UNIGE document Scientific Article
previous document  unige:32698  next document
add to browser collection

Inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) et ostéoporose

Fétique-Will, Anne-Catherine
Published in Revue médicale suisse. 2011, vol. 7, no. 299, p. 1299-304
Abstract Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI.
Keywords Bone Density/drug effectsDepression/drug therapyEvidence-Based MedicineHumansOsteoporosis/chemically induced/prevention & controlRisk FactorsSerotonin Uptake Inhibitors/administration & dosage/adverse effects
PMID: 21793419
Full text
Article (Published version) (1.4 MB) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://rms.medhyg.ch/numero-299-page-1299.htm
Research group Nutrition et os (66)
(ISO format)
FÉTIQUE-WILL, Anne-Catherine, CHEVALLEY, Thierry, RIZZOLI, René. Inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) et ostéoporose. In: Revue médicale suisse, 2011, vol. 7, n° 299, p. 1299-304. https://archive-ouverte.unige.ch/unige:32698

528 hits

1 download


Deposited on : 2013-12-23

Export document
Format :
Citation style :